158 related articles for article (PubMed ID: 37690180)
1. Local control strategies for management of NSCLC with oligoprogressive disease.
Mavrikios A; Remon J; Quevrin C; Mercier O; Tselikas L; Botticella A; Nicolas E; Deutsch E; Besse B; Planchard D; Barlesi F; Le Péchoux C; Levy A
Cancer Treat Rev; 2023 Nov; 120():102621. PubMed ID: 37690180
[TBL] [Abstract][Full Text] [Related]
2. SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L; Kroeze SG; Guckenberger M
Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
[TBL] [Abstract][Full Text] [Related]
4. Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database.
Kroeze SGC; Schaule J; Fritz C; Kaul D; Blanck O; Kahl KH; Roeder F; Siva S; Verhoeff JJC; Adebahr S; Schymalla MM; Glatzer M; Szuecs M; Geier M; Skazikis G; Sackerer I; Lohaus F; Eckert F; Guckenberger M
Radiat Oncol; 2021 Jan; 16(1):4. PubMed ID: 33407611
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic options for oligoprogressive non-small cell lung cancer].
Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
[TBL] [Abstract][Full Text] [Related]
6. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
[TBL] [Abstract][Full Text] [Related]
7. Local Ablative Therapies in Oligometastatic NSCLC: New Data and New Directions.
Lang P; Gomez DR; Palma DA
Semin Respir Crit Care Med; 2020 Jun; 41(3):369-376. PubMed ID: 32450591
[TBL] [Abstract][Full Text] [Related]
8. The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer.
Tam A; Eustace N; Kassardjian A; West H; Williams TM; Amini A
Surg Oncol Clin N Am; 2023 Jul; 32(3):497-514. PubMed ID: 37182989
[TBL] [Abstract][Full Text] [Related]
9. Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
Ng TL; Morgan RL; Patil T; Barón AE; Smith DE; Ross Camidge D
Lung Cancer; 2018 Dec; 126():112-118. PubMed ID: 30527174
[TBL] [Abstract][Full Text] [Related]
10. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
11. Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies.
Jongbloed M; Khosla AA; Bartolomeo V; Jatwani K; Singh R; De Ruysscher DKM; Hendriks LEL; Desai A
Curr Oncol Rep; 2024 Jan; 26(1):80-89. PubMed ID: 38175464
[TBL] [Abstract][Full Text] [Related]
12. A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done.
Belluomini L; Dodi A; Caldart A; Kadrija D; Sposito M; Casali M; Sartori G; Ferrara MG; Avancini A; Bria E; Menis J; Milella M; Pilotto S
Transl Lung Cancer Res; 2021 Jul; 10(7):3369-3384. PubMed ID: 34430373
[TBL] [Abstract][Full Text] [Related]
13. Oligoprogression in non-small cell lung cancer: a narrative review.
Nguyen KT; Sakthivel G; Milano MT; Qiu H; Singh DP
J Thorac Dis; 2022 Dec; 14(12):4998-5011. PubMed ID: 36647502
[TBL] [Abstract][Full Text] [Related]
14. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Juan O; Popat S
Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
[TBL] [Abstract][Full Text] [Related]
15. Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials.
Kim H; Venkatesulu BP; McMillan MT; Verma V; Lin SH; Chang JY; Welsh JW
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):676-683. PubMed ID: 35973624
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
Gan GN; Weickhardt AJ; Scheier B; Doebele RC; Gaspar LE; Kavanagh BD; Camidge DR
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):892-8. PubMed ID: 24462383
[TBL] [Abstract][Full Text] [Related]
17. Oligoprogression in Non-Small Cell Lung Cancer.
Harada D; Takigawa N
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830977
[TBL] [Abstract][Full Text] [Related]
18. How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.
Remon J; Menis J; Levy A; De Ruysscher DKM; Hendriks LEL
Transl Lung Cancer Res; 2021 Jul; 10(7):3486-3502. PubMed ID: 34430382
[TBL] [Abstract][Full Text] [Related]
19. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V; Park HS; Decker RH
Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
[TBL] [Abstract][Full Text] [Related]
20. Management of Oligometastatic Disease in Advanced Non-Small Cell Lung Cancer.
West H
Clin Chest Med; 2020 Jun; 41(2):249-258. PubMed ID: 32402360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]